Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Last Hour:
Last 24 Hours:

Worldwide Solid Tumors Drugs Market 2016 Trend, Analysis and Overview

Friday, September 23, 2016 0:56
% of readers think this story is Fact. Add your two cents.

(Before It's News)

The rising prevalence of various cancers, which has led to innovations and technological advancements, drives the development of new immunotherapy drugs that are more effective than the available drugs to treat solid tumors. 
Solid tumors are an abnormal mass of tissue that do not contain cysts or liquid areas. These may be malignant (cancerous) or benign (not cancerous). They affect bones, organs, and muscles. Based on the type of the cells, solid tumors can be carcinomas, sarcomas, and lymphomas. 

Publisher’s analysts forecast the global solid tumors drugs market to grow at a CAGR of 8.6% during the period 2016-2020.

For more information about this report:   

Covered in this report 
The report covers the present scenario and the growth prospects of the global solid tumors drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded drugs, generics, and biosimilars used to treat solid tumors. It also considers the revenues to be generated from the sales of drugs that are anticipated to be launched into the market along with the decline in revenues from the patent expiries of the branded drugs during the forecast period.

The market is divided into the following segments based on geography: 
- Americas

Publisher’s report, Global Solid Tumors Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. 

Key vendors 
- F. Hoffmann-La Roche
- Novartis
- Celgene
- Johnson & Johnson
- Pfizer


Request Sample Copy at   


Other prominent vendors 
- AbbVie
- AbGenomics 
- ADC Therapeutics 
- Advantagene 
- Agensys 
- Almac Group 
- Ambrx
- Argos Therapeutics
- Array BioPharma 
- Astellas Pharma
- AstraZeneca
- Bayer
- Biogen
- Biotech Pharmaceutical 
- Boehringer Ingelheim 
- Boston Biomedical 
- Celldex Therapeutics
- Chugai Pharmaceutical
- Cold Genesys 
- CTI BioPharma 
- Daiichi Sankyo 
- DNAtrix 
- Ds-Pharma 
- Eleison Pharmaceuticals
- Eli Lilly
- Endo Pharmaceuticals
- Formation Biologics
- Fortress Biotech 
- Genmab 
- GSK 
- Immatics Biotechnologies
- Immunogen 
- Immunomedics 
- Intas Pharmaceuticals
- Kairos Therapeutics
- Kyowa Hakko Kirin 
- MedImmune 
- Merck 
- Mersana Therapeutics 
- Morphotek 
- Neovii Biotech 
- NewLink Genetics
- Northwest Biotherapeutics 
- Novartis
- OncoMed Pharmaceuticals
- Oxford Biotherapeutics 
- Peregrine Pharmaceuticals
- Polaris Pharmaceuticals
- Sanofi
- Seattle Genetics
- Spectrum Pharmaceuticals 
- Stemcentrx
- Synthon Biopharmaceuticals
- TG Therapeutics 
- XBiotech


Inquire for Report at


Contact Us:

Call: +1-646-491-9876

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.